Abstract
Introduction
Hypothyroidism is defined as failure of the thyroid gland to produce sufficient thyroid hormone to meet the metabolic demands of the body. Untreated hypothyroidism can contribute to obesity, hypertension, dyslipidemia, infertility, cognitive impairment, and neuromuscular dysfunction. The prevalence increases with age, and is higher in females than in males 1 .
Hypothyroidism may occur as a result of primary thyroid gland failure (primary hypothyroidism) or insufficient thyroid gland stimulation by the hypothalamus or pituitary gland (secondary hypothyroidism). Primary gland failure can result from congenital abnormalities, autoimmune destruction (Hashimoto disease), iodine deficiency, and infiltrative diseases. Autoimmune thyroid disease is the most common aetiology of hypothyroidism 2 . Iatrogenic forms of hypothyroidism occur after thyroid surgery, radioiodine therapy, and neck irradiation 3 . Disorders generally associated with transient hypothyroidism include postpartum thyroiditis, subacute thyroiditis, silent thyroiditis, and thyroiditis associated with thyroidstimulating hormone (TSH) receptor-blocking antibodies 3 .
Central causes of hypothyroidism typically present with other manifestations of hypothalamic or pituitary dysfunction, and are characterized by inappropriately normal or low levels of TSH relative to insufficient thyroid hormone. Drugs classically associated with thyroid dysfunction include lithium, amiodarone, interferon alfa, interleukin-2, and tyrosine kinase inhibitors 4, 5 .
Clinical presentation
The clinical presentation depends on duration and severity of hypothyroidism. Symptoms commonly associated with hypothyroidism are often nonspecific (Table I) . These include weight gain, fatigue, poor concentration, depression, diffuse muscle pain, and menstrual irregularities. Symptoms with high specificity for hypothyroidism include constipation, cold intolerance, dry skin, proximal muscle weakness, and hair thinning or loss 6 . 
Management
Most patients with hypothyroidism will require lifelong thyroid hormone therapy ( Figure 2 9,13-18 ). The normal thyroid gland makes two thyroid hormones: thyroxine (T4) and triiodothyronine (T3). Although T4 is produced in greater amounts, T3 is the biologically active form. Approximately 80% of T3 is derived from the peripheral conversion of T4 by deiodinase enzymes. However, because T3 preparations have short biologic half-lives, hypothyroidism is treated almost exclusively with synthetic thyroxine preparations. Once absorbed, synthetic thyroxine, like endogenous thyroxine, undergoes deiodination to the more biologically active T3.
The starting dosage of levothyroxine in young, healthy adults for complete replacement is 1.6 µg/kg/day. (Table III  13 -15,19 ). Thyroid hormone is generally taken in the morning, 30 minutes before eating. Calcium and iron supplements should not be taken within four hours of taking levothyroxine, because these supplements may decrease thyroid hormone absorption. Poor adherence to levothyroxine therapy is the most common cause of persistently elevated TSH levels in patients on adequate doses of thyroid hormone. Levothyroxine has a half-life of 7 days so it should always be taken as a single daily dose and at least 6 weeks should pass before repeating thyroid function tests and adjusting the dose, usually by 25 µg per day. Patients feel better within 2-3 weeks. Reduction in weight and periorbital puffiness occurs quickly, but the restoration of skin and hair texture and resolution of any effusions may take 3-6 months 12 . The dose of levothyroxine should be adjusted to maintain serum TSH within the reference range. To achieve this, serum T4 often needs to be in the upper part of the reference range or even slightly raised, because the T3 required for receptor activation is derived exclusively from conversion of T4 within the target tissues, without the usual contribution from thyroid secretion 12 . Patients who have difficulty with morning levothyroxine dosing may find bedtime dosing an effective alternative. In a well-designed study conducted in the Netherlands, bedtime dosing of levothyroxine resulted in lower TSH and higher free T4 levels, but no difference in quality of life 20 . Alternatively, patients with marked difficulty in adhering to a once-daily levothyroxine regimen can safely take their entire week's dosage of levothyroxine once weekly 21 . It is important to measure thyroid function every 1-2 years once the dose of levothyroxine is stabilised 12 . 
Treatment of primary hypothyroidism in adults
Primary hypothyroidism Adult patient 50 years: see 
Older patients and patients with ischaemic heart disease
In older patients and in patients with coronary artery disease, the initial dosage is generally 25 µg or 50 µg daily, with the dosage increased by 25 µg every three to four weeks until the estimated full replacement dose is reached 13, 14 . Thyroid hormone increases heart rate and contractility, and therefore increases myocardial oxygen demand 16 . Consequently, starting at higher doses may precipitate acute coronary syndrome or an arrhythmia. However, there are no high quality studies that show that lower starting doses and slow titration result in fewer adverse effects than full-dose levothyroxine replacement in older patients and patients with ischaemic heart disease 17 .
Pregnancy
Thyroid hormone requirements increase during pregnancy. In one prospective study, 85% of pregnant patients required a median increase of 47% in their thyroid hormone requirements 15 . These increases in levothyroxine dosing were required as early as the fifth week of pregnancy in some patients, which is before the first scheduled prenatal care visit. It is recommended that women on fixed doses of levothyroxine take nine doses each week (one extra dose on two days of the week), instead of the usual seven, as soon as pregnancy is confirmed 15 . Repeat thyroid function tests should be obtained five weeks after the increase in dosage. The increase in thyroid hormone requirement lasts throughout pregnancy.
Patients with persistent symptoms
A small number of patients with hypothyroidism, mostly women, treated with an adequate dose of levothyroxine will report persistent symptoms such as fatigue, depressed mood, and weight gain despite having a TSH level in the lower half of the normal range. Some patients may have an alternative cause for their symptoms; in these patients, a limited laboratory and clinical investigation is reasonable (Table IV) . Combination T3/T4 therapy, in the form of desiccated thyroid hormone preparations or levothyroxine plus liothyronine, is sometimes prescribed for patients with persistent symptoms of hypothyroidism. Endocrinologists for the treatment of hypothyroidism, and a meta-analysis of 11 randomised controlled trials of combination T3/T4 therapy versus T4 monotherapy showed no improvements in bodily pain, depression, or quality of life 22 . A subsequent study showed that a small subset of patients who have a specific type 2 deiodinase polymorphism may benefit from combination therapy 23 .
However, there is insufficient evidence to recommend the use of combination T3/T4 therapy in the treatment of primary hypothyroidism. Numerous medications can affect thyroid hormone levels in patients taking levothyroxine (Table V  24 ,25 
Subclinical hypothyroidism
Subclinical hypothyroidism is a biochemical diagnosis defined by a normal-range free T4 level and an elevated TSH level. Patients may or may not have symptoms attributable to hypothyroidism. On repeat testing, TSH levels may spontaneously normalise in many patients. However, in a prospective study of 107 patients older than 55 years, an initial TSH level greater than 10 to 15 mIU/l was the variable most strongly associated with progression to overt hypothyroidism 26 . Elevated thyroid peroxidase antibody titres also increase the risk of progressing to frank thyroid gland failure, even when the TSH level is less than 10 mIU/l. Treatment with levothyroxine should be considered for patients with initial TSH levels greater than 10 mIU/l, patients with elevated thyroid peroxidase antibody titres, patients with symptoms suggestive of hypothyroidism and TSH levels between 5 and 10 mIU/l, and for patients who are pregnant or are attempting to conceive 11 .
Myxoedema coma
Myxoedema coma is a rare but extremely severe manifestation of hypothyroidism. Mental status changes including lethargy, cognitive dysfunction, and even psychosis, and hypothermia are the hallmark features of myxoedema coma 27 . Hyponatraemia, hypoventilation, and bradycardia can also occur. Because myxoedema coma is a medical emergency with a high mortality rate, even with appropriate treatment, patients should be managed in the intensive care unit where proper ventilatory, electrolyte, and haemodynamic support can be given. Corticosteroids may also be needed. A search for precipitating causes such as infection, cardiac disease, metabolic disturbances, or drug use is critical 27 .
Endocrinology referral is recommended for all patients with suspected myxoedema coma and other indications listed in Table VI. 10 Table VI : Reasons for endocrinology consultation in patients with hypothyroidism
SORT:
The Strength-of-Recommendation Taxonomy; A: Consistent, good-quality patient-oriented evidence; B: Inconsistent or limited-quality patient-oriented evidence; C: Consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.
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